ConnellPH, The use and abuse of amphetamines. Practitioner1968; 200:234–43.
2.
CreeseIBurtDRSynderSH, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science1976; 192:481–3.
3.
CooperJBloomFRothR.The biochemical basis of neuropharmacology. 6th ed.Oxford: Oxford University Press, 1991:285–334.
4.
BiggioGConcasACordaMGGiorgiOSannaESerraM.GABAergic and dopaminergic transmission in the rat cerebral cortex: Effect of stress, anxiolytic and anxiogenic drugs. Pharmacol Ther1990; 48:121–42.
5.
SimonPPanissaudCCostentinJ.Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol Biochem Behav1993; 45:685–90.
6.
SimonPDupuisRCostentinJ.Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res1994; 61:59–64.
7.
TalalaenkoANAbrametsIAStakhovskiiYuVShekhovtsovAAChernikovAVShevchenkoSL, The role of dopaminergic mechanisms on the brain in various models of anxious states. Neurosci Behav Physiol1994; 24:284–8.
8.
McCulloughLDSalamoneJD, Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens. Psychopharmacology1992; 109:379–82.
9.
JaspertAEbertD.Benzodiazepine monotherapy in acute schizophrenia. Nervenarzt1994; 65:62–5.
10.
ChemCHTsaiWJ, Acute amphetamine intoxication with catatonia: A case report. Chung Hua I Hsueh Tsa Chih (Taipei)1993; 51:322–7.
11.
UngvariGSLeungHCLeeTS, Benzodiazepines and the psychopathology of catatonia. Pharmacopsychiatry1994; 27:242–5.
12.
BodkinJA, Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry1990; 51(suppl):41–6, 50–3.
13.
CrowTJHarringtonCA, Etiopathogenesis and treatment of psychosis. Annu Rev Med1994; 45:219–34.